Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EP0062 phase 1/2 study in AR-positive, HER2-negative, ER-positive advanced or metastatic breast cancer
2023-507738-26-00Phase 2Authorised
- Sponsor
- Ellipses Pharma
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label trial of vosilasarm in breast cancer (2 arms), sponsored by Ellipses Pharma. Primary endpoints: Incidence of dose-limiting toxicities, Incidence and severity of adverse events and serious adverse events and 3 more. Planned start Mar 2024; status: authorised.
02
Drugs
vosilasarm
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2023-507738-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507738-26-00.